EP0833641A4 - Treatment and prevention of prostatic disease - Google Patents

Treatment and prevention of prostatic disease

Info

Publication number
EP0833641A4
EP0833641A4 EP96917173A EP96917173A EP0833641A4 EP 0833641 A4 EP0833641 A4 EP 0833641A4 EP 96917173 A EP96917173 A EP 96917173A EP 96917173 A EP96917173 A EP 96917173A EP 0833641 A4 EP0833641 A4 EP 0833641A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
prostatic disease
prostatic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96917173A
Other languages
German (de)
French (fr)
Other versions
EP0833641A1 (en
Inventor
Roy G Smith
William Rosner
Atif M Nakhla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
St Lukes Roosevelt Hospital Center
Original Assignee
Merck and Co Inc
St Lukes Roosevelt Hospital Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc, St Lukes Roosevelt Hospital Center filed Critical Merck and Co Inc
Publication of EP0833641A1 publication Critical patent/EP0833641A1/en
Publication of EP0833641A4 publication Critical patent/EP0833641A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96917173A 1995-06-07 1996-06-05 Treatment and prevention of prostatic disease Withdrawn EP0833641A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48463395A 1995-06-07 1995-06-07
US484633 1995-06-07
PCT/US1996/008873 WO1996040150A1 (en) 1995-06-07 1996-06-05 Treatment and prevention of prostatic disease

Publications (2)

Publication Number Publication Date
EP0833641A1 EP0833641A1 (en) 1998-04-08
EP0833641A4 true EP0833641A4 (en) 2000-04-05

Family

ID=23924956

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917173A Withdrawn EP0833641A4 (en) 1995-06-07 1996-06-05 Treatment and prevention of prostatic disease

Country Status (5)

Country Link
EP (1) EP0833641A4 (en)
JP (1) JPH11507050A (en)
AU (1) AU5984196A (en)
CA (1) CA2222625A1 (en)
WO (1) WO1996040150A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075958A1 (en) * 2002-03-11 2003-09-18 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
JP2004002321A (en) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd Therapeutic agent for sex hormone dependent disease
AU2003207089A1 (en) * 2003-02-14 2004-09-06 Takeda Pharmaceutical Company Limited Preparation for topical administration
WO2006081658A1 (en) * 2005-02-01 2006-08-10 The University Of British Columbia In silico screening for shbg binding ligands via pharmacophore models
WO2007031833A2 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research Novel series of imidazolyl substituted steroidal and indan-1-one derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000095A1 (en) * 1989-06-27 1991-01-10 Michael Cohen Compositions useful as contraceptives in males
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (en) * 1978-04-17 1979-10-25 Schering Ag USE OF ANTIOESTROGEN AND ANTIGONADOTROP ACTING ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000095A1 (en) * 1989-06-27 1991-01-10 Michael Cohen Compositions useful as contraceptives in males
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NAKHLA, A. M. ET AL.: "Sex hormone-binding globulin (SHBG) and estradiol, but not dihydrotestosterone, act together to increase intracellular cAMP in human benign prostatic hypertrophy.", JOURNAL OF UROLOGY, vol. 151, no. 5, 1994, pages 382A, XP002128737 *
PLYMATE S.R. ET AL.: "Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma", J. STEROID BIOCHEM MOL BIOL, vol. 40, no. 4-6, 1991, USA, pages 833 - 9, XP002128736 *
SCHMIDT, K.: "Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate.", FORTSCHRITTE DER MEDIZIN, vol. 101, no. 15, 1983, pages 713 - 6, XP002128738 *
See also references of WO9640150A1 *
VERHELST, J. ET AL: "Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer", CLIN. ENDOCRINOL, vol. 41, no. 4, 1994, Oxford, pages 525 - 30, XP002128735 *

Also Published As

Publication number Publication date
JPH11507050A (en) 1999-06-22
EP0833641A1 (en) 1998-04-08
CA2222625A1 (en) 1996-12-19
WO1996040150A1 (en) 1996-12-19
AU5984196A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
HUP0100627A3 (en) Prevention and treatment of amyloidogenic disease
ZA965088B (en) Methods of preventing or treating allergles
HUP9601808A2 (en) Treatment of arteriosclerosis and xanthoma
EP0831904A4 (en) Treatment and diagnosis of prostate cancer
AU7397094A (en) Prevention and treatment of alzheimer's disease
AU6435398A (en) Prevention and treatment of hepatocellular cancer
IL138692A0 (en) Treatment and prevention of vascular disease
AU6168296A (en) Chloroquine analogs and methods of preventing and treating p lasmodial disease
EP0833641A4 (en) Treatment and prevention of prostatic disease
IL141211A0 (en) Prevention and treatment of viral disease
SG47093A1 (en) Treatment and prevention of prostatic cancer
EP0800396A4 (en) Treatment of hyperandrogenic conditions
EP0866799A4 (en) Apolipoprotein e2 and treatment of alzheimer's disease
GB9516572D0 (en) Prevention and/or treatment of disease
EP0731064A3 (en) Treatment and use of residues from the direct synthesis of organochlor- or chlorsilanes
GB9502689D0 (en) Prevention and treatment of dementia
GB9510961D0 (en) Hemorrhoid treatment and prevention
IL118475A0 (en) Treatment of skin spots and prevention of their formation
AU2003203740A1 (en) Prevention and treatment of amyloidogenic disease
GB9520495D0 (en) Treatment of medical conditions
GB9520494D0 (en) Treatment of medical conditions
GB9520496D0 (en) Treatment of medical conditions
ZA968902B (en) Methods and compositions for treatment of diseases
ZA9810932B (en) Prevention of and treatment of amyloidogenic disease.
EG20171A (en) Treatment of conditions and disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000221

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000426